TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).

Hidetoshi Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.